Biotech Industry Will Look to Benefit From New U.S. Patent System
The Paragon Report Provides Stock Research on AEterna Zentaris and Zalicus
NEW YORK, NY, May 03, 2012 (Menafn - MARKETWIRE via COMTEX) --Biotech stocks have continued to provide investors with strong gainsin 2012. The iShares NASDAQ Biotechnology Index (IBB) is up nearly 20percent year-to-date. The passage of the America Invents Act willlook to benefit the Biotechnology Industry going forward "byenhancing patent quality and the efficiency, objectivity,predictability and transparency of the U.S. patent system," BIOPresident and CEO Jim Greenwood stated in a press release. TheParagon Report examines investing opportunities in the BiotechnologyIndustry and provides equity research on AEterna Zentaris Inc.AEZS and Zalicus Inc. ZLCS.
Access to full reports can be found at:
"Small biotechnology companies rely heavily on their patents toattract investment," and "they will benefit from the improvements toour nation's patent system made by this legislation," addedGreenwood. The America Invents Act (AIA) will shift the patent systemfrom a "first to invent" to a "first to file" system, the first majorchange to the patent system in over 60 years. Under the "first toinvent" system the first inventor to file for a patent will beawarded priority, regardless if the inventor was the first to inventit. Most major countries are already following the "first to file"patent system.
Paragon Report releases regular market updates on the BiotechnologyIndustry so investors can stay ahead of the crowd and make the bestinvestment decisions to maximize their returns. Take a few minutes toregister with us free at www.ParagonReport.com and get exclusiveaccess to our numerous stock reports and industry newsletters.
AEterna Zentaris is an oncology and endocrinology drug developmentcompany currently investigating treatments for various unmet medicalneeds. AEterna Zentaris' pipeline encompasses compounds at all stagesof development, from drug discovery through to marketed products. Thecompany will announce its first quarter 2012 financial and operatingresults before market open on Wednesday, May 9, 2012.
Zalicus, a biopharmaceutical company that discovers and developsnovel treatments for patients suffering from pain andimmuno-inflammatory diseases, recently announced it has completedenrollment with 292 patients enrolled in the SYNERGY trial, a Phase2b clinical trial designed to evaluate the safety and efficacy ofSynavive(R), a low-dose glucocorticoid with the potential foramplified immuno-inflammatory benefits, in patients with rheumatoidarthritis.
Paragon Report provides Market Research focused on equities thatoffer growth opportunities, value, and strong potential return. Westrive to provide the most up-to-date market activities. Weconstantly create research reports and newsletters for our members.The Paragon Report has not been compensated by any of theabove-mentioned companies. We act as independent research portal andare aware that all investment entails inherent risks. Please view thefull disclaimer at: www.ParagonReport.com/disclaimer
SOURCE: Paragon Financial Limited
Copyright 2012 Marketwire, Inc., All rights reserved.